who should not take tirzepatide Explained: The Future of Weight Management Tirzepatide - BIFAT Center

These are reversible upon discontinuation

Phase 3 results published in December 2025 from the TRIUMPH-4 trial a double-blind, placebo-controlled study in 445 adults with obesity or overweight and knee osteoarthritis showed the 12mg dose producing an average of 28.7% body weight reduction at 68 weeks

Furthermore, a physiological change in hemoglobin affinity for oxygen favors oxygen binding in the lung and oxygen release to peripheral tissues

DPP-4 inhibitors were not included in the two tiers because their effectiveness on glycemic control is lower than or equivalent to first- and second-tier agents, as well as for less clinical evidence and relative expense

, , : :